METASTATIC OSTEOSARCOMA TREATMENT MARKET ANALYSIS

Metastatic Osteosarcoma Treatment MarketSize and Trends

Metastatic Osteosarcoma Treatment Market – Drivers

Increasing drug pipeline for malignant bones and soft tissue (Ewing Sarcoma) cancer is expected to drive growth of metastatic osteosarcoma treatment market. For instance, in 2017, Merck & Co., Inc., studies the effects of Pembrolizumab (MK-3475) in patients with relapsed or metastatic osteosarcoma and reported that these patient are not eligible for curative surgery. Currently, study is in phase II clinical trial and is expected to be marketed in 2023. Moreover, Novartis entered into phase II clinical trials for pazopanib for treatment of metastatic osteosarcoma as of March 2018.

Emerging new therapies for metastatic osteosarcoma treatment will further propel growth of the market. For instance, clinical trials for immunotherapy-based drugs and targeted drug therapy is expected to be a preferred option in the near future, owing to less side-effects. The immune therapy drug called immune checkpoint inhibitors can recognize and attack cancer cells exhibiting better outcomes for other cancer types and also studies have showed it is also effective for osteosarcoma treatment. Moreover, engineered monoclonal antibodies are used to stop cancer growth by hampering new blood vessel formation or to inhibit tumor cells by targeting mTOR protein. For instance, Aadi, LLC studies Nivolumab (Opdivo) in combination with ABI-009 (Nab-rapamycin, the mTOR inhibitor) for potential anti-tumor activity for Ewing Sarcoma. The study is in phase II clinical trial, which is expected to complete by 2020.

In case of pediatric osteosarcoma, around 35% of patient fail first-line of therapy, leading to recurrence in metastatic osteosarcoma in lungs. Therefore, development of novel drugs for treatment of lung cancer, due to metastatic osteosarcoma will also contribute to growth of the metastatic osteosarcoma treatment market. For instance, in 2013, Elesion Pharmaceuticals LLC, a pharmaceutical company developing life-saving therapeutics for rare cancers, entered into phase II clinical trials for Inhaled Lipid-complexed Cisplatin (ILC), a novel sustained release formulation of cisplatin in a nanoscale lipid based complex, for pediatric patients with osteosarcoma metastases for lungs. Additionally, inorganic marketing strategies adopted by metastatic osteosarcoma drug market players is expected to aid in the market growth. For instance, in the same year, Inhaled Lipid-complexed Cisplatin orphan drug designation by European Medicines Agency for the treatment of osteosarcoma. Furthermore, in 2015, company entered in partnership with Intelgen Limited, a Hong Kong-based biopharmaceutical company, for specialized novel anti-cancer drug development and commercializing ILC in Chinese market. Moreover, in 2014, Oncolytics Biotech, examined safety and efficacy of Reolysin for the treatment of bone and soft tissue sarcoma metastatic for lungs.